Dengue virus presents an opportunity to develop into a new first-in-class virotherapy. 

The industry has witnessed multiple virotherapies develop, but few have ultimately translated into clinical benefit to cancer patients.

Unlike other oncolytic viruses, our dengue virus is not intended to be a genetically modified virus targeting a specific mutation or to serve as a backbone to deliver a particular antigen target.

Our naturally attenuated strain of dengue virus safely induces a native anti-dengue immune response in humans that is systemic in nature. And in the laboratory, we observe that this immune response results a combination effect of both direct oncolytic tumor killing as well as broad immunostimulatory effects which led to immune-mediated tumor killing. In total, we have observed at least 3 differentiated mechanisms of tumor killing.

PV001-DV’s data summary:

• 21 healthy volunteers treated: validated safety and powerful immune stimulation

• Strong anti-tumor mechanisms of action repeatedly demonstrated in laboratory

• Matching immune stimulation across healthy humans and cancer patient blood samples, further suggesting translatability of science to cancer patients

The above have been repeatedly demonstrated across multiple experiments, conditions, or tumor types.     

We believe that to adequately address treatment-failed late stage cancer, the industry needs to overcome immune evasion and induce both local and systemic effects. In the totality of our publications, we observe that PV001-DV checks the right boxes to produce such powerful effects along multiple mechanisms both local and systemic.